1. Scrip
  3. >>Clinical Trials

AstraZeneca Links With Accent To Target RNA-Modifying Proteins

Pact Spans Discovery, Development And Commercialization

 
• By Sten Stovall

AstraZeneca and Accent Therapeutics will jointly discover, develop and commercialize novel therapeutics targeting RNA-modifying proteins for the treatment of cancer.

DNA_Strand
Deal gives $55m upfront to Accent, a specialist in RNA modification • Source: Shutterstock

In what may be the first R&D pact between a big pharma and a company working in the new area of RNA modification, AstraZeneca PLC and privately held Accent Therapeutics Inc. will together discover, develop and commercialize therapeutics targeting RNA-modifying proteins (RMPs) for use in treating cancer.

Their collaboration, announced 4 June, will focus on targeting RMPs that control many aspects of RNA biology. The science represents...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D

Ireland’s Got Biopharma Talent To Keep Leading The Pack

 
• By Kevin Grogan

The country’s life sciences investment head tells Scrip that it is business as usual for the sector despite the rumblings from across the Atlantic.

Draig Is All Fired Up To Transform Neuropsychiatric Field

 
• By Kevin Grogan

Wales-based group launches with $140m series A.

Immuneering Could Partner Atebimetinib Or Go It Alone After Phase IIa Success

 
• By Alaric DeArment

CEO Ben Zeskind said all options are on the table after atebimetinib showed impressive results in pancreatic cancer.